
Entering the era of prenatal gene therapies
In February 2025, researchers at St Jude Children’s Research Hospital reported the first known in utero use of Roche’s spinal muscular atrophy (SMA) drug Evrysdi (risdiplam) in a human foetus. The foetus was diagnosed with SMA type 1 through prenatal …